SKB264 plus toripalimab for stage III lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two drugs: sacituzumab tirumotecan (SKB264) and toripalimab, for people with stage III non-small cell lung cancer that cannot be surgically removed. The goal is to see if this combination helps shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have stage III non-small cell lung cancer that cannot be removed by surgery.
- Your cancer does not have EGFR, ALK, or ROS1 gene changes.
- You have not received any prior chemotherapy or radiation for your lung cancer.
- You are generally active and able to take care of yourself (ECOG 0 or 1).
- You must be able to provide a sample of your tumor tissue for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, sacituzumab tirumotecan and toripalimab, given before surgery to shrink early-stage NSCLC (stage II to IIIB) that can be removed. The goal is to see if this approach improves outcomes compared to standard treatment.
This trial studies whether adding toripalimab (an immunotherapy medicine) to radiation can improve outcomes for people with operable stage II to IIIA non-small cell lung cancer. It’s designed for cancers that can be fully removed with surgery, and it aims to see if this combination helps more than radiation alone/standard care.
This trial tests combining immunotherapy with chemotherapy for people with stage III non-small cell lung cancer that cannot be removed by surgery. It aims to see if this combination can shrink the tumor and improve outcomes.
This trial tests whether adding toripalimab (an immunotherapy) or toripalimab plus another immunotherapy (tifcemalimab) after standard chemoradiation can help prevent small cell lung cancer from coming back. It is for people with limited-stage disease who have finished initial treatment without the cancer growing.
This study tests whether a drug called toripalimab, given after lung cancer surgery, can help keep the cancer from coming back in people with early-stage non-small cell lung cancer. It uses a blood test (ctDNA) to look for leftover cancer cells and decide who might benefit most.
This trial tests giving toripalimab plus another treatment (JS004) together with standard chemotherapy before lung surgery for stage IIIB–IIIC non-small cell lung cancer. It may help shrink the tumor and make surgery more effective, and it compares different treatment combinations.
Hear when a new Non-small Cell Lung Cancer Stage III trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.